Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies
September 9, 2024
In-depth scientific research drives long term conviction and support through company building, private financing and public markets.
Friendly Capital
Flexible capital structure and friendly terms to support our high growth portfolio companies
Rigorous Due Diligence Process
Long term, high conviction investor, built on thorough scientific and financial expertise
Unique Support for our Portfolio Companies
Leverage the global LifeSci Partners network to drive value creation and accelerate business plans
The LifeSci team played an integral role in the formation and successful launch of Engage Therapeutics. At all times, I considered them part of my team. From the beginning, LifeSci guided me through the investor story, outreach process and strategy for closing.
We are honored by the magnitude of support from such an impressive syndicate of investors, especially during these turbulent times.
We are thrilled to have an incredibly strong, committed network of investors and plan to continue extending our leadership in the decentralized clinical trial market.
Paul Yook
Partner & CIO
Ryan Cinalli, PhD
Chief Scientific Officer
Ira Kalfus, MD
Chief Medical Officer
Julie Mauser
Director, Business Development
Brittany Amendola, CPA
Chief Financial Officer
Jeff Seo
Managing Director, Head of APAC for LifeSci Partners
August 2020, Series D-1
Science 37 is a decentralized CRO making the promise of v...
March 2019, Series A April 2020, Series B
Erasca is a San Diego based biotech company creating a new generation of onc...
May 2019, Series C
Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disea...
January 2019, Series B
Beta Bionics is a medical device company developing the breakthrough iLet system which combines...
December 2018, Series B
Akero is a biotechnology company focused on serious metabolic diseases with a lead program, AK...
June 2018, Series B
Attune is a clinical-stage biotechnology company focused on novel small-molecule therapeutics for...
June 2018, Series C
Metacrine is a San Diego based biotechnology company with exceptional chemistry capabilities and a...
March 2018, Series B
Orasis is a clinical-stage pharmaceutical company developing an innovative eye drop for the treat...
March 2018, At-the-Market
Nasdaq: NVUS
Novus is a specialty pharma company focused on disorders of the near, nose...
January 2018, Series D
November 2018, RTO
Columbia Care is one of the largest medical cannabis manufacturers and...
November 2017, Series B
July 2018, IPO - Nasdaq: ALLK
Allakos is developing AK002, a first-in-class antibody...
March 2017, Series B
January 2018, NASDAQ: RCKT
Rocket Pharma is developing...
September 2017, Series A
Engage is developing Staccato® Alprazolam, a small, easy-to-use hand-held drug-device com...
Dr. Kalfus was Chief Medical Officer at Thar Pharmaceuticals until its acquisition by Grunenthal in 2016. He was previously Vice President of Medical Affairs at Lev Pharmaceuticals, where he led the clinical development for Cinryze, the first HAE prophylaxis therapy, approved by the FDA in 2008. Upon the acquisition of Lev by ViroPharma Inc. in 2008, he consulted on the Cinryze commercial launch and expansion as well as investor relations activities for ViroPharma. Dr. Kalfus is consulting Medical Director at RedHill Biopharma Ltd. and directs two phase III clinical programs. His other positions have included Aetna/US Healthcare (Medical Director), Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement). Dr. Kalfus completed residency in Internal Medicine at Long Island Jewish Medical Center and graduated from Albert Einstein College of Medicine with an M.D. and Columbia University with a B.A. in Biology.
Visit Homepage